DI NUNNO, VINCENZO
 Distribuzione geografica
Continente #
NA - Nord America 1.439
EU - Europa 867
AS - Asia 288
AF - Africa 67
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 2.667
Nazione #
US - Stati Uniti d'America 1.435
SE - Svezia 177
GB - Regno Unito 169
VN - Vietnam 132
IT - Italia 111
DE - Germania 110
IE - Irlanda 80
CN - Cina 75
CH - Svizzera 55
BE - Belgio 39
IN - India 39
TG - Togo 28
FI - Finlandia 24
RU - Federazione Russa 24
CI - Costa d'Avorio 22
FR - Francia 20
BG - Bulgaria 17
JP - Giappone 14
ZA - Sudafrica 12
AT - Austria 11
EE - Estonia 11
JO - Giordania 9
UA - Ucraina 7
SK - Slovacchia (Repubblica Slovacca) 5
HK - Hong Kong 4
NG - Nigeria 4
NL - Olanda 4
AU - Australia 3
BD - Bangladesh 3
TR - Turchia 3
MY - Malesia 2
NI - Nicaragua 2
SG - Singapore 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
CA - Canada 1
EU - Europa 1
LB - Libano 1
MA - Marocco 1
MX - Messico 1
NO - Norvegia 1
PL - Polonia 1
RO - Romania 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
Totale 2.667
Città #
Chandler 239
Fairfield 150
Southend 144
Ashburn 102
Dublin 80
Seattle 77
Princeton 72
Houston 70
Woodbridge 67
Dong Ket 65
Wilmington 59
Bern 55
Cambridge 52
Ann Arbor 49
Brussels 37
Lomé 28
Berlin 25
Helsinki 24
Abidjan 22
Bologna 22
Beijing 18
Sofia 17
Westminster 15
Redwood City 12
Turin 12
New York 10
Vienna 10
Amman 9
Boydton 9
Des Moines 9
Nanjing 9
Olalla 9
Redmond 9
Falls Church 8
San Diego 8
Florence 6
Glasgow 6
London 6
Naples 6
Shenyang 6
Kyoto 5
Milan 5
Montescudo 5
Žilina 5
Abeokuta 4
Bentivoglio 4
Chicago 4
Hebei 4
Jinan 4
Kumar 4
Tianjin 4
Torino 4
Bühl 3
Cardiff 3
Changsha 3
Hangzhou 3
Kuban 3
New Haven 3
Pescara 3
Sacramento 3
Zhengzhou 3
Boston 2
Bremen 2
Canberra 2
Casalgrande 2
Central 2
Clearwater 2
Costa Mesa 2
Dearborn 2
Frankfurt Am Main 2
Groningen 2
Haikou 2
Isera 2
Istanbul 2
Kilburn 2
Kuala Lumpur 2
Los Angeles 2
Managua 2
Mīrpur 2
Nanchang 2
Ningbo 2
Norwalk 2
Padova 2
Parabiago 2
Saint Petersburg 2
San Francisco 2
Sha Tin Wai 2
Taichung 2
Altamira 1
Amsterdam 1
Andover 1
Bagnara di Romagna 1
Bo 1
Boardman 1
Braine-l'alleud 1
Breda 1
Buenos Aires 1
Casablanca 1
Cedar Knolls 1
Cesena 1
Totale 1.778
Nome #
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 162
Circulating tumor cells in genitourinary tumors 146
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 139
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 126
Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors 116
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 114
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 110
Immune checkpoint inhibitors for metastatic bladder cancer 101
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 95
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 92
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 90
The human microbiota and prostate cancer: Friend or foe? 80
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 75
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 72
Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. 71
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008 61
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 61
The clinical and prognostic role of ALK in glioblastoma 59
Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study 57
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem 56
Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review 54
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases 53
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 51
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? 50
Discovering the molecular landscape of meningioma: The struggle to find new therapeutic targets 49
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 48
Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study 48
Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3 47
Rare Primary Central Nervous System Tumors in Adults: An Overview 46
Glioblastoma: Emerging treatments and novel trial designs 43
Idh1 non-canonical mutations and survival in patients with glioma 40
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment 40
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 40
IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas 39
Meningioma: Not always a benign tumor. A review of advances in the treatment of meningiomas 30
Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light 29
Machine learning in neuro-oncology: toward novel development fields 25
null 24
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 22
Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. 18
Cabazitaxel in metastatic prostate cancer 16
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? 15
Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back? 13
Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors 11
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 8
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 8
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 7
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 7
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 7
The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target? 7
The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma 6
Optimizing renal function and outcome of patients with cT2 renal cell carcinoma 5
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue 5
N-Myc a key gene promoting a worst prostate cancer progression 4
Pembrolizumab plus axitinib: A new treatment option for patients with metastatic renal cell carcinoma 2
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462–8 2
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 2
Future perspectives for personalized immunotherapy in renal cell carcinoma 2
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 1
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes 1
Totale 2.808
Categoria #
all - tutte 8.798
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.798


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201927 0 0 0 0 0 0 0 0 4 11 0 12
2019/2020472 54 11 0 26 51 41 60 69 68 43 29 20
2020/2021338 46 12 29 3 21 4 6 6 35 14 7 155
2021/2022609 12 18 15 24 53 22 9 61 56 59 187 93
2022/20231.020 90 106 42 100 64 120 37 68 197 40 59 97
2023/2024296 51 63 27 37 22 45 17 26 8 0 0 0
Totale 2.808